Catalyze Capital
Overview
Catalyze Capital is a closed-end venture capital fund that invests in early-stage European companies across the life science, sustainable, and deep tech sectors.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Neuro Event Labs | Feb 2025 | VC Round | Co-investor |
| Melt&Marble | Dec 2025 | Series A | Co-investor |
| Breye Therapeutics | Sep 2026 | Series A | Co-investor |
| Gesynta Pharma AB | Jul 2025 | Series B | Co-investor |
Key People
Marlene Végh
Venture Partner
Jalal Es-Sbai
Investment partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Catalyze Capital based?
Catalyze Capital is headquartered in Amsterdam, Netherlands.
When was Catalyze Capital founded?
Catalyze Capital was founded in 2024.
How many portfolio companies does Catalyze Capital have?
Catalyze Capital has 4 portfolio companies in Caplight's dataset.
What are some companies in Catalyze Capital's portfolio?
Portfolio companies visible on Caplight include Neuro Event Labs, Melt&Marble, Breye Therapeutics, Gesynta Pharma AB.
What was Catalyze Capital's most recent investment shown here?
Catalyze Capital's most recent investment in this portfolio sample was in Breye Therapeutics in 2026.
What sectors does Catalyze Capital focus on?
Catalyze Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Energy & Sustainability, AI, Data & Cloud Infrastructure.
What company stages does Catalyze Capital focus on?
Catalyze Capital typically invests at the Early stage.
What is Catalyze Capital's AUM?
Catalyze Capital's assets under management are estimated at up to $27.0M.